These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25164637)

  • 1. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
    Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
    J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic crisis after neostigmine administration in a dog with acquired focal myasthenia gravis.
    Foy DS; Trepanier LA; Shelton GD
    J Vet Emerg Crit Care (San Antonio); 2011 Oct; 21(5):547-51. PubMed ID: 22316202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005-2011).
    Barnoon I; Shamir MH; Aroch I; Bdolah-Abram T; Srugo I; Konstantin L; Chai O
    J Vet Emerg Crit Care (San Antonio); 2016; 26(1):116-24. PubMed ID: 26458162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
    Muscle Study Group
    Neurology; 2008 Aug; 71(6):394-9. PubMed ID: 18434639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995).
    Dewey CW; Bailey CS; Shelton GD; Kass PH; Cardinet GH
    J Vet Intern Med; 1997; 11(2):50-7. PubMed ID: 9127290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.
    Hanisch F; Wendt M; Zierz S
    Eur J Med Res; 2009 Aug; 14(8):364-6. PubMed ID: 19666397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine therapy for acquired myasthenia gravis in five dogs.
    Dewey CW; Coates JR; Ducoté JM; Meeks JC; Fradkin JM
    J Am Anim Hosp Assoc; 1999; 35(5):396-402. PubMed ID: 10493415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Oskarsson B; Rocke DM; Dengel K; Richman DP
    Neurology; 2016 Mar; 86(12):1159-63. PubMed ID: 26850977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.
    Janssen SP; Phernambucq M; Martinez-Martinez P; De Baets MH; Losen M
    J Neuroimmunol; 2008 Sep; 201-202():111-20. PubMed ID: 18667242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
    Phan C; Sanders DB; Siddiqi ZA
    Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
    Meriggioli MN; Rowin J
    Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of idiopathic immune-mediated hemolytic anemia with mycophenolate mofetil in five dogs.
    West LD; Hart JR
    J Vet Emerg Crit Care (San Antonio); 2014; 24(2):226-31. PubMed ID: 24251650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary immune-mediated hemolytic anemia with mycophenolate mofetil in two cats.
    Bacek LM; Macintire DK
    J Vet Emerg Crit Care (San Antonio); 2011 Feb; 21(1):45-9. PubMed ID: 21288293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of mycophenolate mofetil to treat immune-mediated skin disease in 14 dogs - a retrospective evaluation.
    Ackermann AL; May ER; Frank LA
    Vet Dermatol; 2017 Apr; 28(2):195-e44. PubMed ID: 27943548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.